Semaglutide linked to 26% lower 5-year predicted dementia risk
alz-journals.onlinelibrary.wiley.com
August 15, 2026
1 min read
🔥🔥🔥🔥🔥
58/100
Summary
Semaglutide is associated with a 26% reduction in the predicted risk of developing dementia over five years. This finding suggests potential cognitive benefits of the drug beyond its use for weight management and diabetes.
Community Sentiment
Positives
- Semaglutide has shown remarkable effects on inflammation and arthritis, proving to be more than just a weight loss tool, which is a game-changer for many.
- After a year on semaglutide, I lost 40 pounds and cleared my liver fat, which is a huge health win at age 50.
- The potential of GLP-1s like semaglutide to lower dementia risk opens doors for preventative health measures that could save millions in the long run.
- Tirzepatide is being touted as a potential cure for T2D, indicating rapid advancements in diabetes treatment that could revolutionize patient care.
Concerns
- Some users report worrying side effects from semaglutide, including fatigue and hypoglycemia, raising red flags about its long-term safety.
- The skepticism around semaglutide's effectiveness is palpable, with some claiming the benefits might just be due to weight loss, not the drug itself.
- Concerns about the lack of thorough testing for newer drugs like retatrutide highlight the anxiety around injecting unproven substances into our bodies.
- The claim that semaglutide impacts dementia risk is dismissed by some as clinically meaningless, suggesting a disconnect between marketing and scientific reality.